Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.09 EUR
11.48 M EUR
211.70 M EUR
140.50 M
About TG Therapeutics, Inc.
Sector
CEO
Michael Sean Weiss
Headquarters
Morrisville
Website
Founded
1993
FIGI
BBG005GHDVY3
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of NKB2 is 27.62 EUR — it has increased by 1.39% in the past 24 hours. Watch TG THERAPEUTICS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange TG THERAPEUTICS INC stocks are traded under the ticker NKB2.
NKB2 stock has fallen by −6.20% compared to the previous week, the month change is a −8.27% fall, over the last year TG THERAPEUTICS INC has showed a 68.98% increase.
We've gathered analysts' opinions on TG THERAPEUTICS INC future price: according to them, NKB2 price has a max estimate of 53.19 EUR and a min estimate of 9.67 EUR. Watch NKB2 chart and read a more detailed TG THERAPEUTICS INC stock forecast: see what analysts think of TG THERAPEUTICS INC and suggest that you do with its stocks.
NKB2 reached its all-time high on Feb 8, 2021 with the price of 51.00 EUR, and its all-time low was 2.17 EUR and was reached on Nov 18, 2013. View more price dynamics on NKB2 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
NKB2 stock is 2.63% volatile and has beta coefficient of 1.40. Track TG THERAPEUTICS INC stock price on the chart and check out the list of the most volatile stocks — is TG THERAPEUTICS INC there?
Today TG THERAPEUTICS INC has the market capitalization of 4.35 B, it has decreased by −3.38% over the last week.
Yes, you can track TG THERAPEUTICS INC financials in yearly and quarterly reports right on TradingView.
TG THERAPEUTICS INC is going to release the next earnings report on Mar 4, 2025. Keep track of upcoming events with our Earnings Calendar.
NKB2 earnings for the last quarter are 0.02 EUR per share, whereas the estimation was 0.03 EUR resulting in a −33.33% surprise. The estimated earnings for the next quarter are 0.14 EUR per share. See more details about TG THERAPEUTICS INC earnings.
TG THERAPEUTICS INC revenue for the last quarter amounts to 75.34 M EUR, despite the estimated figure of 73.38 M EUR. In the next quarter, revenue is expected to reach 105.59 M EUR.
NKB2 net income for the last quarter is 3.48 M EUR, while the quarter before that showed 6.42 M EUR of net income which accounts for −45.74% change. Track more TG THERAPEUTICS INC financial stats to get the full picture.
No, NKB2 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jan 10, 2025, the company has 264.00 employees. See our rating of the largest employees — is TG THERAPEUTICS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. TG THERAPEUTICS INC EBITDA is −176.04 K EUR, and current EBITDA margin is 9.01%. See more stats in TG THERAPEUTICS INC financial statements.
Like other stocks, NKB2 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TG THERAPEUTICS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So TG THERAPEUTICS INC technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating TG THERAPEUTICS INC stock shows the buy signal. See more of TG THERAPEUTICS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.